Estradiol benzoate/estradiol phenylpropionate/testosterone propionate/testosterone phenylpropionate/testosterone isocaproate

EB/EPP/TP/TPP/TiC
Combination of
Estradiol benzoateEstrogen
Estradiol phenylpropionateEstrogen
Testosterone propionateAndrogen; Anabolic steroid
Testosterone phenylpropionateAndrogen; Anabolic steroid
Testosterone isocaproateAndrogen; Anabolic steroid
Clinical data
Trade namesEstandron Prolongatum, Lynandron Prolongatum, Mixogen
Other namesEB/EPP/TP/TPP/TiC
Routes of
administration		Intramuscular injection
Identifiers
CAS Number
PubChem CID
ChemSpider

Estradiol benzoate/estradiol phenylpropionate/testosterone propionate/testosterone phenylpropionate/testosterone isocaproate (EB/EPP/TP/TPP/TiC), sold under the brand names Estandron Prolongatum, Lynandron Prolongatum, and Mixogen, was an injectable combination medication of the estrogens estradiol benzoate (EB) and estradiol phenylpropionate (EPP) and the androgens/anabolic steroids testosterone propionate (TP), testosterone phenylpropionate (TPP), and testosterone isocaproate (TiC) which was used in menopausal hormone therapy for women.[1][2] It was also used to suppress lactation in postpartum women.[3][4]

The medication was provided in the form of 1 mL ampoules and 2 mL vials containing 1 mg/mL EB, 4 mg/mL EPP, 20 mg/mL TP, 40 mg/mL TPP, and 40 mg/mL TiC in an oil solution and was administered by intramuscular injection.[1][5][6] EB/EPP/TP/TPP/TiC reportedly has a duration of about 14 days.[7]

Estandron Prolongatum, Lynandron Prolongatum, and Mixogen were all introduced for medical use by 1956.[8][9] Oral tablet products with the same brand names of Estandron, Lynandron, and Mixogen, containing ethinylestradiol and methyltestosterone, were marketed around the same time, and should not be confused with the injectable products.[8][1][10] Estandron Prolongatum, Lynandron Prolongatum, and Mixogen remained marketed as late as the 1980s.[6][4][11] EB/EPP/TP/TPP/TiC appears to no longer be marketed.[12][13][14]

Androgen replacement therapy formulations and dosages used in women
RouteMedicationMajor brand namesFormDosage
OralTestosterone undecanoateAndriol, JatenzoCapsule40–80 mg 1x/1–2 days
MethyltestosteroneMetandren, EstratestTablet0.5–10 mg/day
FluoxymesteroneHalotestinTablet1–2.5 mg 1x/1–2 days
NormethandroneaGinecosideTablet5 mg/day
TiboloneLivialTablet1.25–2.5 mg/day
Prasterone (DHEA)b–Tablet10–100 mg/day
SublingualMethyltestosteroneMetandrenTablet0.25 mg/day
TransdermalTestosteroneIntrinsaPatch150–300 μg/day
AndroGelGel, cream1–10 mg/day
VaginalPrasterone (DHEA)IntrarosaInsert6.5 mg/day
InjectionTestosterone propionateaTestovironOil solution25 mg 1x/1–2 weeks
Testosterone enanthateDelatestryl, Primodian DepotOil solution25–100 mg 1x/4–6 weeks
Testosterone cypionateDepo-Testosterone, Depo-TestadiolOil solution25–100 mg 1x/4–6 weeks
Testosterone isobutyrateaFemandren M, FolivirinAqueous suspension25–50 mg 1x/4–6 weeks
Mixed testosterone estersClimacteronaOil solution150 mg 1x/4–8 weeks
Omnadren, SustanonOil solution50–100 mg 1x/4–6 weeks
Nandrolone decanoateDeca-DurabolinOil solution25–50 mg 1x/6–12 weeks
Prasterone enanthateaGynodian DepotOil solution200 mg 1x/4–6 weeks
ImplantTestosteroneTestopelPellet50–100 mg 1x/3–6 months
Notes: Premenopausal women produce about 230 ± 70 μg testosterone per day (6.4 ± 2.0 mg testosterone per 4 weeks), with a range of 130 to 330 μg per day (3.6–9.2 mg per 4 weeks). Footnotes: a = Mostly discontinued or unavailable. b = Over-the-counter. Sources: See template.

See also

References

  1. 1 2 3 Hans Hermann Julius Hager; Walther Kern; Paul Heinz List; Hermann Josef Roth (29 July 2013). Hagers Handbuch der Pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Ärzte und Medizinalbeamte: Wirkstoffgruppen II Chemikalien und Drogen (A-AL). Springer-Verlag. pp. 141, 157, 185. ISBN 978-3-662-25655-8.
  2. ↑ Josef Kimmig (14 March 2013). Therapie der Haut- und Geschlechtskrankheiten. Springer-Verlag. pp. 508–. ISBN 978-3-642-94850-3.
  3. ↑ Helmuth Vorherr (2 December 2012). The Breast: Morphology, Physiology, and Lactation. Elsevier Science. pp. 201–. ISBN 978-0-323-15726-1.
  4. 1 2 Defoort P, Thiery M, Baele G, Clement D, Dhont M (December 1987). "Bromocriptine in an injectable retard form for puerperal lactation suppression: comparison with Estandron prolongatum". Obstet Gynecol. 70 (6): 866–9. PMID 3684122.
  5. ↑ Current Medicine and Drugs. 1964. p. 32. Mixogen Injection is now available in single vials of 2 ml which replace the 1 ml ampoules hitherto supplied. It is widely used for the suppression of lactation and the single 2 ml dose pack is specially designed for obstetric indications.
  6. 1 2 Sharma CP, Chandy T (November 1989). "Influence of steroid hormones on protein-platelet interaction at the blood-polymer interface". Biomaterials. 10 (9): 609–16. doi:10.1016/0142-9612(89)90115-4. PMID 2611310. Mixogen, one 1 ml ampoule contains oestradiol benzoate I.P., 1 mg, oestradiol phenyl propionate, 4 mg, testosterone propionate I.P., 20 mg, testosterone phenyl propionate B.P., 40 mg and testosterone isocaproate B.P., 40 mg.
  7. ↑ Ufer, Joachim (1 January 1978). Hormontherapie in der Frauenheilkunde: Grundlagen und Praxis [Hormone Therapy in Gynecology: Principles and Practice] (in German) (5 ed.). de Gruyter. p. 276. ISBN 978-3110066647. OCLC 924728827.
  8. 1 2 Kahr, H.; Müller, H. A. (1956). "Behandlung der Menstruationsstörungen". Konservative Therapie der Frauenkrankheiten. pp. 1–85. doi:10.1007/978-3-7091-5694-0_1. ISBN 978-3-7091-5696-4.
  9. ↑ "Neue Spezialitäten". Klinische Wochenschrift. 37 (13): 719–720. 1959. doi:10.1007/BF01478227. ISSN 0023-2173. S2CID 13380961.
  10. ↑ Front Matter. (1953). The British Medical Journal, 2(4835). Retrieved from http://www.jstor.org/stable/20312464
  11. ↑ Kaiser R (March 1984). "Duration of the climacteric syndrome in women treated by hormonal substitution and in controls". Maturitas. 5 (3): 207–13. doi:10.1016/0378-5122(84)90054-9. PMID 6727694.
  12. ↑ "Estradiol". Drugs.com.
  13. ↑ Sweetman, Sean C., ed. (2009). "Sex hormones and their modulators". Martindale: The Complete Drug Reference (36th ed.). London: Pharmaceutical Press. pp. 2100, 2124–2125. ISBN 978-0-85369-840-1.
  14. ↑ "IBM Watson Health Products: Please Login". www.micromedexsolutions.com.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.